Table 3 Adjusted hazard ratios of the different pathway-based signatures in two validation cohorts.
From: Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
GSE14814 | GSE13213 | |||
|---|---|---|---|---|
Variable | HR (95% CI) a | P valuea | HR (95% CI) a | P valuea |
HMGB1/RAGE signalling pathway-based risk score | ||||
Gene Signature | 1.64(1.24-2.18) | 0.0005 | 2.56(1.65-3.97) | <0.0001 |
Age | 1.08(1.02-1.13) | 0.0033 | 1.01(0.98-1.03) | 0.6500 |
Sex | 2.12(1.00-4.49) | 0.0503 | 1.30(0.71-2.38) | 0.3910 |
Stage | ||||
I | 1.00 | 1.00 | ||
II | 1.61(0.78-3.30) | 0.1950 | 1.83(0.74-4.55) | 0.1920 |
III | 4.75(2.51-8.97) | <0.0001 | ||
Beta-adrenergic receptor regulation of ERK pathway | ||||
Gene Signature | 2.21(1.53-3.17) | <0.0001 | 1.70(1.39-2.07) | <0.0001 |
Age | 1.07(1.01-1.12) | 0.014 | 1.01(0.98-1.04) | 0.3964 |
Sex | 1.62(0.76-3.44) | 0.2080 | 1.80(0.97-3.33) | 0.0603 |
Stage | ||||
I | 1.00 | 1.00 | ||
II | 1.36(0.66-2.81) | 0.4080 | 1.73(0.70-4.26) | 0.2371 |
III | 4.92(2.58-9.38) | <0.0001 | ||
Clathrin-coated vesicle cycle pathway | ||||
Gene Signature | 1.49(1.21-1.84) | 0.0002 | 1.56(1.33-1.84) | <0.0001 |
Age | 1.07(1.02-1.13) | 0.0094 | 1.01(0.98-1.04) | 0.5290 |
Sex | 2.18(1.01-4.71) | 0.0468 | 1.25(0.68-2.30) | 0.4730 |
Stage | ||||
I | 1.00 | 1.00 | ||
II | 1.18(0.56-2.50) | 0.6571 | 1.06(0.42-2.67) | 0.8960 |
III | 3.60(1.92-6.76) | <0.0001 | ||
Combined pathway-based risk (CPBR) | ||||
Gene Signature | 2.72(1.80-4.11) | <0.0001 | 1.71(1.45-2.03) | <0.0001 |
Age | 1.07(1.01-1.13) | 0.0163 | 1.01(0.98-1.04) | 0.4970 |
Sex | 1.81(0.85-3.84) | 0.1225 | 1.41(0.76-2.61) | 0.2820 |
Stage | ||||
I | 1.00 | 1.00 | ||
II | 1.35(0.64-2.85) | 0.4323 | 1.21(0.47-3.14) | 0.6920 |
III | 5.04(2.65-9.55) | <0.0001 | ||
